Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats

Journal of Gastroenterology

Volumn 40, Issue 3, 2005, Pages 260-265

  Mikami, Ken Ichiro ^a   Goto, Takashi ^a   Miura, Kouichi ^a   Ohshima, Shigetoshi ^a   Yoneyama, Kazuo ^a   Lin, Jiun Guey ^a   Watanabe, Daisuke ^a   Segawa, Daisuke ^a   Kataoka, Ei ^a   Shibuya, Tomomi ^a   Watanabe, Sumio ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute liver failure; Gabexate mesilate; Interleukin 1 ; Protease inhibitor; Tumor necrosis factor

Indexed keywords

AMINOTRANSFERASE; CARBON TETRACHLORIDE; GABEXATE MESILATE; INTERLEUKIN 1BETA; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; HISTOPATHOLOGY; LETHAL DOSE; LIVER EXAMINATION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; RAT STRAIN; SURVIVAL RATE;

ANIMALS; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GABEXATE; INTERLEUKIN-1; LETHAL DOSE 50; LIVER; LIVER DISEASES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SERINE PROTEINASE INHIBITORS; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 18144366584     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-004-1534-3     Document Type: Article

References (41)

1. Williams R, Riordan SM. Fulminant hepatic failure. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's disease of the liver, 9th ed. Philadelphia: Lippincott Williams&Wilkins, 2002. p. 941-70.
2. Sherlock S, Dooley J. Disease of the liver and biliary system, 11th ed. Oxford: Blackwell, 2002. p. 111-26.
3. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991;13:364-75.
4. Izumi S, Hughes RD, Langley PG, Pernambuco JR, Williams R. Extent of the acute phase response in fulminant hepatic failure. Gut 1994;35:982-6.
5. Rosser BG, Gores GJ. Liver cell necrosis: Cellular mechanisms and clinical implications. Gastroenterology 1995;108:252-75.
6. Muto Y, Nouri-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988;ii:72-4.
7. Nagaki M, Muto Y, Ohnishi H, Moriwaki H. Significance of tumor necrosis factor (TNF) and interleukin-1 in the pathogenesis of fulminant hepatitis: Possible involvement of serine protease in TNF-mediated liver injury. Gastroenterol Jpn 1991;26:448-55.
8. DeCicco LA, Rikans LE, Tutor CG, Hornbrook KR. Serum and liver concentration of tumor necrosis factor-α and interleukin-1β following administration of carbon tetrachloride to male rats. Toxicol Lett 1998;98:115-21.
9. Paques EP, Romisch J. Comparative study on the in vitro effectiveness of antithrombotic agents. Thromb Res 1991;64:11-21.
10. Mayumi T, Ura H, Arata S, Kitamura N, Kiriyama I, Shibuya K, et al. Evidence-based clinical practice guidelines for acute pancreatitis: proposals. J Hepatobiliary Pancreat Surg 2002;9:413-22.
11. Pezzilli R, Miglioli M. Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis 2001;33:49-57.
12. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000;47:1147-50.
13. Tamaki S, Wada H, Hiyoyama K, Shimura M, Minamikawa K, Wakita Y, et al. Treatment of disseminated intravascular coagulation with gabexate mesilate. Clin Ther 1993;15:1076-84.
14. Okamura T, Niho Y, Itoga T, Chiba S, Miyake M, Kotsuru M, et al. Treatment of disseminated intravascular coagulation and its prodromal stage with gabaxate mesilate (FOY): A multi-center trial. Acta Haematol 1993;90:120-4.
15. Taenaka N, Shimada Y, Hirata T, Nishijima MK, Takezawa J, Yoshiya I, et al. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983;11:735-8.
16. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996;24:1047-53.
17. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, et al. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 1997;25:874-9.
18. Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27:1958-64.
19. Jung SE, Yun IJ, Youn YK, Lee JE, Ha J, Noh DY, et al. Effect of protease inhibitor on ischemia-reperfusion injury to rat liver. World J Surg 1999;23:1027-31.
20. Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY. Hepatocyte protection by a protease inhibitor against ischemia/ reperfusion injury of human liver. J Am Coll Surg 2002;195:41-50.
21. Yuksel M, Okajima K, Uchiba M, Okabe H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-α production by inhibiting activation of both nuclear factor-κB and activation protein-1 in human monocytes. J Pharmacol Exp Ther 2003;305:298-305.
22. Morio LA, Chiu H, Sprowles KA, Zhou P, Heck DE, Gordon MK, et al. Distinctive roles of tumor necrosis factor-α and nitric oxide in acute liver injury induced by carbon tetrachloride in mice. Toxicol Appl Pharmacol 2001;172:44-51.
23. Bruccoleri A, Gallucci R, Germolec D, Blackshear P, Simeonova P, Thurman RG, et al. Induction of early-mediate genes by tumor necrosis factor-α contributes to liver repair following chemical induced hepatotoxicity. Hepatology 1997;25:133-41.
24. Czaja MJ, Xu J, Alt E. Prevention of carbon tetrachloride-induced rat liver injury by soluble tumor necrosis factor receptor. Gastroenterology 1995;108:1849-54.
25. Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY: [Ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vitro effect on coagulo-fibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981;24:445-52.
26. Tamura Y, Hirado M, Okamura K, Minato Y, Fujii S. Synthetic inhibitors of trypsin, plasmin, kallilrein, thrombin, C1r - and C1 esterase. Biochim Biophys Acta 1977;484:417-22.
27. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001;184:258-74.
28. Lo CJ, Fu M, Kim B. Macrophage TNF mRNA expression is modulated by protease inhibitors. J Surg Res 1997;69:408-12.
29. Clawson GA. Mechanisms of carbon tetrachloride hepatotoxicity. Pathol Immunopathol Res 1989;8:104-12.
30. Williams AT, Burk RF. Carbon tetrachloride hepatotoxicity: An example of free radical-mediated injury. Semin Liver Dis 1990; 10:279-84.
31. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 2001;71:226-40.
32. Armendariz-Borunda J, Seyer JM, Postlethwaite AE, Kang AH. Kupffer cells from carbon tetrachloride-injured rat livers produce chemotactic factors for fibroblasts and monocytes: The role of tumor necrosis factor-alpha. Hepatology 1991;14:895-900.
33. Currin RT, Caldwell-Kenkel JC, Lichtman SN, Bachmann S, Takei Y, Kawano S, et al. Production by Carolina rinse solution, acidotic pH, and glycine against lethal reperfusion injury to sinusoidal endothelial cells of rat livers stored for transplantation. Transplantation 1996;11:1549-58.
34. Perira SP, Langley PG, Williams R. The management of abnormalities of hemostasis in acute liver failure. Semin Liver Dis 1996; 16:403-14.
35. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis 1986;6:159-63.
36. Lee TY, Mai LM, Wang GJ, Chiu JH, Lin YL, Lin HC. Protective mechanism of Salvia miltiorrhiza on carbon tetrachloride-induced acute hepatotoxicity in rats. J Pharmacol Sci 2003;91:202-10.
37. Sheweita SA, Abd El-Gabar M, Bastawy M. Carbon tetrachloride changes the activity of cytochrome P450 system in the liver of male rats: Role of antioxidants. Toxicology 2001;169:83-92.
38. Arosio B, Gangliano N, Fusaro LM, Parmeggiani L, Tagliabue J, Galetti P, et al. Aloe-emodin quinine pretreatment reduces acute liver injury induced by carbon tetrachloride. Pharmacol Toxicol 2000;87:229-33.
39. Campo GM, Squadrito F, Ceccarelli S, Calo M, Avenoso A, Campo S, et al. Reduction of carbon tetrachloride-induced rat liver injury by IRFI 042, a novel dual vitamin E-like antioxidant. Free Radical Res 2001;34:379-93.
40. Al-Shabanah OA, Alam K, Nagi MN, Al-Rikabi AC, Al-Bekairi AM. Protective effect of aminoguanidine, a nitric oxide synthesis inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci 2000;66:265-70.
41. Cagen SZ, Klaassen CD. Protection of carbon tetrachloride-induced hepatotoxicity by zinc; role of metallothionein. Toxicol Appl Toxicol 1979;51:107-16.